Non-Small Cell Lung Cancer (NSCLC) stands out as the canonical example of a disease transformed by Companion Diagnostics (CDx), serving as a blueprint for precision medicine in other cancer types. Historically treated with broad chemotherapy regimens, NSCLC care has been revolutionized by the identification of numerous actionable genomic alterations, each corresponding to a specific targeted therapy. Key biomarkers, including mutations in EGFR, rearrangements in ALK and ROS1, and expression of PD-L1, have all been mandated to have corresponding CDx tests for patient selection. This intricate molecular landscape necessitates a comprehensive diagnostic approach, making NSCLC a major segment for high-complexity, multiplexed CDx assays. Clinically, a patient's treatment pathway is now dictated by the results of a single, often NGS-based, tumor profiling test.

The clinical success in NSCLC, demonstrated by dramatically improved progression-free survival and overall survival rates in biomarker-positive patients receiving targeted therapy compared to those receiving standard chemotherapy, has cemented the CDx requirement. Furthermore, the evolving complexity, such as the need to monitor for acquired resistance mutations (EGFR T790M) during treatment, has propelled the adoption of liquid biopsy CDx. The sheer volume of tests performed and the constant influx of new drug-CDx pairings for NSCLC make it the largest disease segment driving the Companion Diagnostics for Oncology Market Size. The learnings from NSCLC—from the regulatory co-development model to the establishment of quality assurance networks for molecular testing—are now being applied to other complex tumor types, including colorectal cancer, melanoma, and breast cancer, confirming its role as the market's archetypal success story.